The Filing Desk

Aardvark Therapeutics

AARD · Nasdaq · Health Care · Financials, fiscal 2024 to 2025

AARD · Last close · November 19, 2026
$1.00
Value Aardvark Therapeutics yourself

Aardvark Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$54 million. The diluted share count rose 391.1%.

AARDVARK THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 23, 2026 · 0001193125-26-119770 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$58M
 
Free cash flow
−$54M
 
Return on equity
−221.6%
 
Market cap
$22M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Aardvark Therapeutics does

Aardvark Therapeutics is a clinical-stage drug developer: it has no approved products and no sales yet. It is working on pills meant to reduce hunger in people with metabolic diseases. Its drugs act on bitter taste receptors in the gut, which, when triggered, release the body's own hormones that signal fullness to the brain.

Its lead drug, ARD-101, is being tested for the constant, extreme hunger of Prader-Willi Syndrome, a rare genetic disorder. A second program, ARD-201, combines ARD-101 with an existing diabetes drug and was being tested for keeping weight off after people stop losing weight on GLP-1 drugs. In February 2026 the company paused enrollment and dosing in its late-stage ARD-101 trial and its follow-on study after reversible heart-related findings in a study of healthy volunteers, and it then also paused the two ARD-201 trials while it reviews the data with the FDA.

Aardvark went public in February 2025 and received net proceeds of about $87.5 million from the offering. It had 40 full-time employees in the United States at the end of February 2026.

Its biggest risks, as it describes them

  • It has no approved products, has lost money since it began, and needs a lot more funding to keep developing its drugs.
  • Its business depends heavily on ARD-101, whose main trial is paused after heart-related findings.
  • Trials may show safety problems or fail to show the drugs work, delaying or ending approval.
  • Prader-Willi Syndrome is rare, so finding and enrolling enough patients for trials may be hard.
  • Larger drug companies may bring rival hunger and obesity treatments to market first or sell them more successfully.
From Aardvark Therapeutics's annual report on Form 10-K, filed March 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Aardvark Therapeutics lost money in fiscal 2025: a net loss of $58 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY24FY25
Cash and short-term investments74110
Debt incl. finance leases——
Net debt (negative means net cash)——
Net debt to EBITDA——
Debt to equity——
Interest coverage——
Current ratio15.1x10.6x
Quick ratio15.1x10.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Aardvark Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Aardvark Therapeutics says to expect

  • Cash runway: existing cash and short-term investmentsBased on current operating plans, Aardvark believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund projected operations through 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 13, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $144,630 of Aardvark Therapeutics shares on the open market, and 1 insider sold $394,930, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026Nelson SunSee RemarksSold plan62,000$5.18$321,160Form 4
Sep 10, 2026Nelson SunSee RemarksSold plan14,754$5.00$73,770Form 4
Dec 11, 2025Tien-Li LeeChief Executive Officer, Director, 10% ownerBought7,000$14.49$101,430Form 4
Dec 11, 2025Nelson SunChief Financial OfficerBought3,000$14.40$43,200Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY25
Piotroski F-score—
Rule of 40—
Altman Z''9.47
Accruals ratio−3.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY25
Net income is positiveFail
Cash from operations is positiveFail
Return on assets rose—
Cash from operations exceeds net incomePass
Debt fell relative to assets—
Current ratio roseFail
Share count didn't riseFail
Gross margin rose—
Revenue rose relative to assets—
F-score—
Companies that report no gross profit are scored on the other eight.

Compare

Put Aardvark Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Aardvark TherapeuticsFY25——————
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

2 years of figures

Fiscal yearFY24FY25
Income statement
Revenue—0
Revenue growth——
Gross profit——
Research and development1749
Operating income−23−63
Net income−21−58
Diluted EPS (US$)−5.15−2.93
Diluted shares (millions)420
Cash flow
Cash from operations−18−54
Capital expenditure00
Free cash flow−18−54
Dividends paid00
Share buybacks00
Acquisitions00
Stock-based compensation04
Balance sheet at fiscal year end
Cash and short-term investments74110
Debt incl. finance leases——
Total assets78117
Total liabilities510
Shareholders' equity−55107
Margins and ratios
Gross margin——
Operating margin——
Net margin——
Free cash flow margin——
Rule of 40 (growth + FCF margin)——
Return on capital——
Return on equity—−221.6%
Return on assets—−59.2%
Net debt to EBITDA——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Aardvark Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Aardvark Therapeutics.